Title: Founder and CEO
Workplace: Prelude Therapeutics
Alma Maters: Andhra Pradesh Agricultural University, University of Florida
Boards: Acellus Health, University of Delaware’s Research Foundation and Biopharmaceutical Innovation
What was your first job? “In my first job, I was a scientist in a 20-person startup company Proscript in Boston, where we discovered one of the most impactful medicines in blood cancers called Velcade.”
Kris Vaddi spent 14 years at Incyte where he helped develop one of its most important drugs, Jakafi. After two decades in the biopharmaceutical industry though, he wanted to return to the grassroots innovation of a startup, and left to found Prelude Therapeutics in 2016. The company has drawn increasing international attention for its work on small molecule inhibitors, a developing therapy that is more targeted in approach with fewer side effects than traditional cancer therapies like chemotherapy or radiation. Prelude is working on treatments for blood, brain, and lymph node cancers. The promise of Prelude’s work drove it to become the newest publicly traded company to IPO from Delaware, raising hundreds of millions of dollars from investors since 2020, and has opened a new headquarters and research lab at the Chestnut Run Innovation & Science Park.
